Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2025 07:30 ET | Source: Vima Therapeutics

Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders

- $60 million Series A led by Atlas Venture, and founded by an expert team of physicians and scientists - VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being...